Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 806

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 806
---
RO managed all operational aspects of the study including site activation and patient enrollment. The Company was required to make certain payments under the agreement related to patient enrollment milestones. For the three and six months ended December 31, 2023, the Company has recognized a recovery of $ 512(2022 - $ 1,075expense) and an expense of $ 563(2022 - $ 1,075), respectively, for this study in relation to clinical site initiation and patient enrollment.

On October 31, 2023, the Company announced that preliminary topline results from this registrational study for VAL-083did not perform better than the current standards of care in glioblastoma. As a result, the Company announced that it has terminated the development of VAL-083.In the six months ended December 31, 2023, the remaining deposit of $ 1,075was offset against amounts owing to the CRO and the agreement with the CRO was terminated with an additional final cost of $ 1,000, of which $ 600was paid at December 31, 2023, and $ 400was paid subsequent to December 31, 2023.

In the six months ended December 31, 2023, the Company paid $ 114as a deposit with a CRO for the management of the Company’s 15-patientstudy of REM-001for cutaneous metastatic breast cancer (“CMBC”).

| 4 | Clinical trials grant |

Effective July 1, 2023, the Company was awarded a $ 2,000Small Business Innovation Research grant from the National Institutes of Health (“NIH”) to support the clinical development of REM-001for the treatment of cutaneous metastatic breast cancer. The grant will be received in twotranches: approximately $ 1,250for the period July 1, 2023, to June 30, 2024, and approximately $ 750for the period July 1, 2024, to June 30, 2025. As a result of receiving the grant, the REM-001, 15-patientclinical trial will be re-started.The grant is expended to the Company as a reimbursement of expenditures incurred. During the three and six months ended December 31, 2023, the Company received $ 197(2022 - nil) and $ 210(2022 - nil), respectively, for grants received against research and development expenditures in the period.

The grant is